BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO


10/2/2009 8:29:30 AM

Bookmark and Share

ST. PAUL, Minn., Oct. 1 /PRNewswire/ -- Algos Therapeutics Inc., a Minnesota-based global preclinical contract research organization (CRO) today announces the selection of Dr. Ganesh Iyer as its new president and CEO. Dr. Iyer will assume his new responsibilities immediately.

"We were incredibly fortunate to have attracted such a uniquely qualified executive as Dr. Iyer to lead Algos," stated Gary Smaby, Algos Board Chair and managing partner for Quatris Fund, the Company's lead investor. "Dr. Iyer possesses the rare combination of scientific expertise and business acumen needed to lead Algos in the deployment of the Company's new service-based CRO model focused on assisting leading pharmaceutical companies in bringing their technological breakthroughs to the marketplace," adds Mr. Smaby.

Until recently, Dr. Iyer was Director of Strategic Analysis and Business Operations at MDS Pharma Services. Dr. Iyer has over 16 years of strategic and business development experience with prominent biotech and high-tech companies ranging from R&D start-ups to F500 companies, including ZymoGenetics/Novo Nordisk, Xcyte Therapies, SkeleTech, MDS Pharma Services and Microsoft. Dr. Iyer holds a Ph.D. in Chemical Engineering from Purdue University and an M.B.A. from Seattle University.

"I am very excited about joining Algos and look forward to working with an excellent team to achieving our mission and goal to become the premier preclinical in vivo pain research services company," commented Dr. Iyer.

About Algos Therapeutics:

Founded as Algos Therapeutics, Inc. in 2003, the company recently changed its corporate identity to Algos Preclinical Services to reflect its new strategic market positioning as a US-based preclinical, in vivo CRO that provides contract research services to pharmaceutical, biotech and medical device markets. Algos Preclinical supports the development of its customers' products from its facilities in St. Paul, MN USA.

Visit Algos' website at www.Algosinc.com

SOURCE Algos Preclinical Services

CONTACT: Frank Eichmann, Director, Business Development of Algos
Preclinical Services, +1-651-209-0733, feichmann@algosinc.com

Web site: http://www.Algosinc.com/



Read at BioSpace.com

Algos
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES